Author

Nazneen B. Khan

Institution: University of North Carolina at Chapel Hill

Observed institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center

OpenAlex ID: A5111084226

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

2023 · Yucai Wang, Melissa C. Larson, et al. · Blood · 10

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma

2025 · Yucai Wang, Melissa C. Larson, et al. · Blood Advances · 7

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

2026 · Yucai Wang, Melissa C. Larson, et al. · Blood Cancer Journal

Works count: 3

Citation count: 17

H-index: 2

I10-index: 1